this looks like good news, but I am hesitant because of all of the geopolitical complexities. Iran
appears to be leveraging the situation to advance their interests.
Oil Falls Towards $125 as Investors Weigh US Import Ban
https://www.theepochtimes.com/mkt_app/oil-falls-towards-125-as-investors-weigh-us-import-ban_4326355.html
📌Follow and Share👇🏻
🔬🧬 @RWMaloneMD
appears to be leveraging the situation to advance their interests.
Oil Falls Towards $125 as Investors Weigh US Import Ban
https://www.theepochtimes.com/mkt_app/oil-falls-towards-125-as-investors-weigh-us-import-ban_4326355.html
📌Follow and Share👇🏻
🔬🧬 @RWMaloneMD
www.theepochtimes.com
Oil Falls Towards $125 as Investors Weigh US Import Ban
LONDON—Oil slipped towards $125 a barrel in volatile trading on Wednesday as investors assessed the U.S. ban of ...
pretty sure this is good news….
https://childrenshealthdefense.org/defender/washington-health-board-against-covid-vaccine-mandate-k-12-students/
📌Follow and Share👇🏻
🔬🧬 @RWMaloneMD
https://childrenshealthdefense.org/defender/washington-health-board-against-covid-vaccine-mandate-k-12-students/
📌Follow and Share👇🏻
🔬🧬 @RWMaloneMD
Children's Health Defense
Washington Health Board Advisory Group Recommends Against COVID Vaccine Mandate for K-12 Students
An advisory group of experts convened by the Washington State Board of Health voted against requiring COVID-19 vaccines for K-12 students in the state’s schools. Meanwhile, Florida’s surgeon general released its official guidance recommending against the…
is this a punishment?
World Economic Forum Freezes ‘All Relations’ With Russia, Putin
https://www.theepochtimes.com/mkt_app/world-economic-forum-freezes-all-relations-with-russia-putin_4327761.html
📌Follow and Share👇🏻
🔬🧬 @RWMaloneMD
World Economic Forum Freezes ‘All Relations’ With Russia, Putin
https://www.theepochtimes.com/mkt_app/world-economic-forum-freezes-all-relations-with-russia-putin_4327761.html
📌Follow and Share👇🏻
🔬🧬 @RWMaloneMD
The Epoch Times
The Epoch Times | Breaking News, Latest News, World News and Videos
Get the latest breaking news, in-depth reporting, and insightful analysis on a wide range of topics, including politics, culture, and world events | The Epoch Times is a trusted source for real news and information that is free from influence and bias.
👍1🤡1
Forwarded from COVID19 VACCINE VICTIMS AND FAMILIES
FUREY: Ontario reveals deaths caused by COVID much lower than previously reported
https://torontosun.com/opinion/columnists/furey-ontario-reveals-deaths-caused-by-covid-much-lower-than-previously-reported
Join ➣ 👉@COVID19VACCINEVICTIMSANDFAMILIES
https://torontosun.com/opinion/columnists/furey-ontario-reveals-deaths-caused-by-covid-much-lower-than-previously-reported
Join ➣ 👉@COVID19VACCINEVICTIMSANDFAMILIES
torontosun
FUREY: Ontario reveals deaths caused by COVID much lower than previously reported
Ontario says the number of deaths caused by COVID-19 is much lower than the story the previous statistics told.
👍1
United Airlines to Let Unvaccinated Workers Return
https://www.wsj.com/articles/united-airlines-to-let-unvaccinated-workers-return-11646869723
📌Follow and Share👇🏻
🔬🧬 @RWMaloneMD
https://www.wsj.com/articles/united-airlines-to-let-unvaccinated-workers-return-11646869723
📌Follow and Share👇🏻
🔬🧬 @RWMaloneMD
WSJ
WSJ News Exclusive | United Airlines to Let Unvaccinated Workers Return
The move allows staffers with exemptions from the carrier’s U.S. Covid-19 vaccine mandate to return from unpaid leave or from non-customer-facing roles, people familiar with the decision said.
Conditions Contributing to COVID-19 Deaths, by State and Age, Provisional 2020-2022 | Data | Centers for Disease Control and Prevention
https://data.cdc.gov/NCHS/Conditions-Contributing-to-COVID-19-Deaths-by-Stat/hk9y-quqm
📌Follow and Share👇🏻
🔬🧬 @RWMaloneMD
https://data.cdc.gov/NCHS/Conditions-Contributing-to-COVID-19-Deaths-by-Stat/hk9y-quqm
📌Follow and Share👇🏻
🔬🧬 @RWMaloneMD
people have said “if Ukrainian biolabs was the reason why Russia invaded, why didn’t Russia say so before they invaded.”. well, apparently they did.
https://thebulletin.org/2022/02/russian-media-spreading-disinformation-about-us-bioweapons-as-troops-mass-near-ukraine/
📌Follow and Share👇🏻
🔬🧬 @RWMaloneMD
https://thebulletin.org/2022/02/russian-media-spreading-disinformation-about-us-bioweapons-as-troops-mass-near-ukraine/
📌Follow and Share👇🏻
🔬🧬 @RWMaloneMD
Bulletin of the Atomic Scientists
Russian media spreading disinformation about US bioweapons as troops mass near Ukraine
Unsubstantiated allegations about US bioweapons or malicious biological research near Russia are being echoed at the highest levels of the Russian government. State media are repeating the claims. The Kremlin’s alleged proxy media outlets are writing about…
Not good. this could get ugly.
https://www.thegatewaypundit.com/2022/03/breaking-exclusive-hunter-biden-firm-rosemont-seneca-invested-firm-tied-ukrainian-biolabs/
📌Follow and Share👇🏻
🔬🧬 @RWMaloneMD
https://www.thegatewaypundit.com/2022/03/breaking-exclusive-hunter-biden-firm-rosemont-seneca-invested-firm-tied-ukrainian-biolabs/
📌Follow and Share👇🏻
🔬🧬 @RWMaloneMD
The Gateway Pundit
BREAKING EXCLUSIVE: Hunter Biden Firm Rosemont Seneca Invested in Firm Tied to Ukrainian Biolabs | The Gateway Pundit | by Joe…
Hunter Biden’s firm Rosemont Seneca provided capital for the firms behind the creation of Biolabs in Ukraine. We heard on Tuesday from the US State Department that there were US Biolabs in Ukraine.
Media is too big
VIEW IN TELEGRAM
Official trailer Dr. Robert Malone in Headwind 2, People in the eye of the storm.
📌Follow and Share👇🏻
🔬🧬 @RWMaloneMD
📌Follow and Share👇🏻
🔬🧬 @RWMaloneMD
Media is too big
VIEW IN TELEGRAM
"Dr. Robert Malone and Dr. Angelina Farella: Doctors Fighting Misinformation"
📌Follow and Share👇🏻
🔬🧬 @RWMaloneMD
📌Follow and Share👇🏻
🔬🧬 @RWMaloneMD
Forwarded from Dr David Martin
Media is too big
VIEW IN TELEGRAM
WHO Says It Advised Ukraine to Destroy Pathogens in Laboratories: Report
https://www.theepochtimes.com/mkt_app/who-says-it-advised-ukraine-to-destroy-pathogens-in-laboratories-report_4330947.html
📌Follow and Share👇🏻
🔬🧬 @RWMaloneMD
https://www.theepochtimes.com/mkt_app/who-says-it-advised-ukraine-to-destroy-pathogens-in-laboratories-report_4330947.html
📌Follow and Share👇🏻
🔬🧬 @RWMaloneMD
The Epoch Times
WHO Says It Advised Ukraine to Destroy Pathogens in Laboratories: Report
Crimes against free will - COVID grand jury - Part II
https://www.thedesertreview.com/opinion/columnists/crimes-against-free-will---covid-grand-jury---part-ii/article_7b553d18-9fe2-11ec-bf0f-371e7699513c.html
📌Follow and Share👇🏻
🔬🧬 @RWMaloneMD
https://www.thedesertreview.com/opinion/columnists/crimes-against-free-will---covid-grand-jury---part-ii/article_7b553d18-9fe2-11ec-bf0f-371e7699513c.html
📌Follow and Share👇🏻
🔬🧬 @RWMaloneMD
The Desert Review
Crimes against free will - COVID grand jury - Part II
On February 26, 2022, Reiner Fuellmich's grand jury held the final day of hearings with expert testimony on eugenics and transhumanism. The first speaker, Patrick Wood, introduced the topic as
The changing epidemiology of SARS-CoV-2
We have come a long way since the start of the COVID-19 pandemic—from hoarding toilet paper and wiping down groceries to sending our children back to school and vaccinating billions. Over this period, the global community of epidemiologists and evolutionary biologists has also come a long way in understanding the complex and changing dynamics of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), the virus that causes COVID-19. In this Review, we retrace our steps through the questions that this community faced as the pandemic unfolded. We focus on the key roles that mathematical modeling and quantitative analyses of empirical data have played
https://www.science.org/doi/10.1126/science.abm4915
📌Follow and Share👇🏻
🔬🧬 @RWMaloneMD
We have come a long way since the start of the COVID-19 pandemic—from hoarding toilet paper and wiping down groceries to sending our children back to school and vaccinating billions. Over this period, the global community of epidemiologists and evolutionary biologists has also come a long way in understanding the complex and changing dynamics of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), the virus that causes COVID-19. In this Review, we retrace our steps through the questions that this community faced as the pandemic unfolded. We focus on the key roles that mathematical modeling and quantitative analyses of empirical data have played
https://www.science.org/doi/10.1126/science.abm4915
📌Follow and Share👇🏻
🔬🧬 @RWMaloneMD
Science News: Ivermectin Is Associated with Decreased Mortality as well as improved outcomes, more data on myocarditis after vaccination.
Not holding my breath for apologies from medical boards, legacy and social media
Treatment with Ivermectin Is Associated with Decreased Mortality in COVID-19 Patients: Analysis of a National Federated Database
International Journal of Infectious Diseases Volume 116, Supplement, March 2022
Abstract Highlights:
- Comparing ivermectin versus remdesivir with an endpoint of reduced mortality, using a large national database.
- Patients groups were controlled for (matched) both comorbidities (unlike that NY Board of health pediatric vaccine study) as well as treatments that may affect COVID-19 survival outcomes: age, gender, race, ethnicity, nicotine use diabetes mellitus, obesity, chronic lower respiratory disease, ischemic heart diseases, tocilizumab, glucocorticoids, or ventilator use.
- After using propensity score matching and adjusting for potential confounders, ivermectin was associated with reduced mortality vs remdesivir p<0.0001.
Abstract: We retrospectively identified adults (≥18 years) with a recorded COVID-19 infection between January 1, 2020 and July 11, 2021. We compared those with recorded use of ivermectin, but not remdesivir, against those with recorded use of remdesivir, but not ivermectin. We controlled for the following demographics, comorbidities, and treatments that may affect COVID-19 survival outcomes: age, gender, race, ethnicity, nicotine use diabetes mellitus, obesity, chronic lower respiratory disease, ischemic heart diseases, tocilizumab, glucocorticoids, or ventilator use. We measured association with mortality as the primary outcome, with significance assessed at p<0.05.
Results: There were a total of 1,761,060 possible COVID-19 patients based on ICD-10 diagnostic terms and confirmatory lab results. Prior to controlling, our analysis yielded 41,608 patients who had COVID-19 resulting in two unique cohorts that were treated with either ivermectin (1,072) or remdesivir (40,536). Within the ivermectin cohort, average age was 51.9 + 17.8 years, 43% were male, 60% had glucocorticoids and 1% required ventilator support. In the remdesivir cohort, average age was 62.0 + 16.0 years, 54% were male, 64% had glucocorticoids and 2% required ventilator support. After using propensity score matching and adjusting for potential confounders, ivermectin was associated with reduced mortality vs remdesivir (OR 0.308, 95% CI (0.198,0.479)),Risk Difference -5.224%, CI (-7.079%,-3.369%), p <0.0001.
Conclusion: Ivermectin use was associated with decreased mortality in patients with COVID-19 compared to remdesivir. To our knowledge, this is the largest association study of patients with COVID-19, mortality and ivermectin. Further double-blinded placebo-controlled RCTs with large samples are required for definite conclusion. In the future, if more publications are published with the similar result to the current analyses, the certainty of evidence will increase.
📌Follow and Share👇🏻
🔬🧬 @RWMaloneMD
Not holding my breath for apologies from medical boards, legacy and social media
Treatment with Ivermectin Is Associated with Decreased Mortality in COVID-19 Patients: Analysis of a National Federated Database
International Journal of Infectious Diseases Volume 116, Supplement, March 2022
Abstract Highlights:
- Comparing ivermectin versus remdesivir with an endpoint of reduced mortality, using a large national database.
- Patients groups were controlled for (matched) both comorbidities (unlike that NY Board of health pediatric vaccine study) as well as treatments that may affect COVID-19 survival outcomes: age, gender, race, ethnicity, nicotine use diabetes mellitus, obesity, chronic lower respiratory disease, ischemic heart diseases, tocilizumab, glucocorticoids, or ventilator use.
- After using propensity score matching and adjusting for potential confounders, ivermectin was associated with reduced mortality vs remdesivir p<0.0001.
Abstract: We retrospectively identified adults (≥18 years) with a recorded COVID-19 infection between January 1, 2020 and July 11, 2021. We compared those with recorded use of ivermectin, but not remdesivir, against those with recorded use of remdesivir, but not ivermectin. We controlled for the following demographics, comorbidities, and treatments that may affect COVID-19 survival outcomes: age, gender, race, ethnicity, nicotine use diabetes mellitus, obesity, chronic lower respiratory disease, ischemic heart diseases, tocilizumab, glucocorticoids, or ventilator use. We measured association with mortality as the primary outcome, with significance assessed at p<0.05.
Results: There were a total of 1,761,060 possible COVID-19 patients based on ICD-10 diagnostic terms and confirmatory lab results. Prior to controlling, our analysis yielded 41,608 patients who had COVID-19 resulting in two unique cohorts that were treated with either ivermectin (1,072) or remdesivir (40,536). Within the ivermectin cohort, average age was 51.9 + 17.8 years, 43% were male, 60% had glucocorticoids and 1% required ventilator support. In the remdesivir cohort, average age was 62.0 + 16.0 years, 54% were male, 64% had glucocorticoids and 2% required ventilator support. After using propensity score matching and adjusting for potential confounders, ivermectin was associated with reduced mortality vs remdesivir (OR 0.308, 95% CI (0.198,0.479)),Risk Difference -5.224%, CI (-7.079%,-3.369%), p <0.0001.
Conclusion: Ivermectin use was associated with decreased mortality in patients with COVID-19 compared to remdesivir. To our knowledge, this is the largest association study of patients with COVID-19, mortality and ivermectin. Further double-blinded placebo-controlled RCTs with large samples are required for definite conclusion. In the future, if more publications are published with the similar result to the current analyses, the certainty of evidence will increase.
📌Follow and Share👇🏻
🔬🧬 @RWMaloneMD
👍1
Myocarditis Following COVID-19 BNT162b2 Vaccination Among Adolescents in Hong Kong JAMA Pediatr. Research Letter. Published online February 25, 2022. doi:10.1001/jamapediatrics.2022.0101
Highlights:
- In weighing the risk of myocarditis against the benefit of preventing severe COVID-19, Norway, the UK, and Taiwan have suspended the second dose of mRNA vaccine for adolescents.
- Similarly, adolescents (aged 12-17 years) in Hong Kong have been recommended to receive 1 dose of BNT162b2 instead of 2 doses 21 days apart since September 15, 2021.
- 84% of the hospitalizations (36 of 43) occurred after the second dose.
- For the second dose, one out of every 4515 children developed myocarditis-related hospitalization. Note that this is an average for both genders.
- For the first dose, one out of every 32,051 children developed myocarditis-related hospitalization.
📌Follow and Share👇🏻
🔬🧬 @RWMaloneMD
Highlights:
- In weighing the risk of myocarditis against the benefit of preventing severe COVID-19, Norway, the UK, and Taiwan have suspended the second dose of mRNA vaccine for adolescents.
- Similarly, adolescents (aged 12-17 years) in Hong Kong have been recommended to receive 1 dose of BNT162b2 instead of 2 doses 21 days apart since September 15, 2021.
- 84% of the hospitalizations (36 of 43) occurred after the second dose.
- For the second dose, one out of every 4515 children developed myocarditis-related hospitalization. Note that this is an average for both genders.
- For the first dose, one out of every 32,051 children developed myocarditis-related hospitalization.
📌Follow and Share👇🏻
🔬🧬 @RWMaloneMD
IVERMECTIN RE-PURPOSING FOR COVID-19 TREATMENT OUTPATIENTS IN MILD STAGE IN PRIMARY HEALTH CARE CENTERS
medRxiv 2021.03.29.21254554; doi: https://doi.org/10.1101/2021.03.29.21254554
This article is a preprint
Highlights:
- This was a cluster Assigned Clinical Trial (2:1) in outpatients, n = 234. The subjects were divided into experimental groups (EG: n = 110) and control groups (CG: n = 62). The EG received ivermectin orally 4 drops of 6 mg = 24 mg every 7 days for 4 weeks. All participants were diagnosed by positive RT-PCR for COVID-19 and were evaluated by clinical examination, at the beginning and the end of protocol.
- Both groups were similar in age, sex, and comorbidities
- A significant reduction in the symptom numbers was observed in the ivermectin treatment group after starting treatment (p = 0·0026).
- Although, medical examination from 10th to 14th day, showed a progressive reduction of the percentage symptom numbers, these were not significative in both groups.
- A higher proportion of medical release was observed in EG (98·2%) vs CG (87·1%) (p = 0·003).
- The ivermectin group showed 8 times more chance of receiving medical release than the control group (OR 7·99, 95% CI: 1·64 −38·97, p = 0·003).
Interpretation
- Treatment with ivermectin in outpatients with mild stage COVID-19 disease managed to slightly reduce the symptom numbers.
- This treatment improved the clinical state to obtain medical release, even in the presence of comorbidities.
- The treatment with ivermectin could significantly prevent the evolution to serious stages since the Experimental group did not present any patient with referral to critical hospitalization.
📌Follow and Share👇🏻
🔬🧬 @RWMaloneMD
medRxiv 2021.03.29.21254554; doi: https://doi.org/10.1101/2021.03.29.21254554
This article is a preprint
Highlights:
- This was a cluster Assigned Clinical Trial (2:1) in outpatients, n = 234. The subjects were divided into experimental groups (EG: n = 110) and control groups (CG: n = 62). The EG received ivermectin orally 4 drops of 6 mg = 24 mg every 7 days for 4 weeks. All participants were diagnosed by positive RT-PCR for COVID-19 and were evaluated by clinical examination, at the beginning and the end of protocol.
- Both groups were similar in age, sex, and comorbidities
- A significant reduction in the symptom numbers was observed in the ivermectin treatment group after starting treatment (p = 0·0026).
- Although, medical examination from 10th to 14th day, showed a progressive reduction of the percentage symptom numbers, these were not significative in both groups.
- A higher proportion of medical release was observed in EG (98·2%) vs CG (87·1%) (p = 0·003).
- The ivermectin group showed 8 times more chance of receiving medical release than the control group (OR 7·99, 95% CI: 1·64 −38·97, p = 0·003).
Interpretation
- Treatment with ivermectin in outpatients with mild stage COVID-19 disease managed to slightly reduce the symptom numbers.
- This treatment improved the clinical state to obtain medical release, even in the presence of comorbidities.
- The treatment with ivermectin could significantly prevent the evolution to serious stages since the Experimental group did not present any patient with referral to critical hospitalization.
📌Follow and Share👇🏻
🔬🧬 @RWMaloneMD
medRxiv
IVERMECTIN REPROPOSING FOR COVID-19 TREATMENT OUTPATIENTS IN MILD STAGE IN PRIMARY HEALTH CARE CENTERS
Background The emergence of COVID-19 requires alternative treatments based on the reuse of drugs as a strategy to prevent the progression of the disease in patients infected with SARS-COV-2. The goal was to evaluate the use of ivermectin in mild stage outpatients…
Notable Pfizer news: but not yet able to interpret the significance- Stay tuned for further updates. Edited - news on the street. This form is routine - not an issue.
Here is the SEC filing link
📌Follow and Share👇🏻
🔬🧬 @RWMaloneMD
Here is the SEC filing link
📌Follow and Share👇🏻
🔬🧬 @RWMaloneMD